TARGETED TRANSURETHRAL MICROWAVE THERMOTHERAPY VERSUS ALPHA-BLOCKADE IN BENIGN PROSTATIC HYPERPLASIA: OUTCOMES AT 18 MONTHS
|
|
- Paul Wilkinson
- 8 years ago
- Views:
Transcription
1 ADULT UROLOGY TARGETED TRANSURETHRAL MICROWAVE THERMOTHERAPY VERSUS ALPHA-BLOCKADE IN BENIGN PROSTATIC HYPERPLASIA: OUTCOMES AT 18 MONTHS BOB DJAVAN, CHRISTIAN SEITZ, CLAUS G. ROEHRBORN, MESUT REMZI, MITRA FAKHARI, MATTHIAS WALDERT, ALI BASHARKHAH, BERNHARD PLANZ, MIKE HARIK, AND MICHAEL MARBERGER ABSTRACT Objectives. To compare directly the efficacy, safety, and durability of targeted transurethral microwave thermotherapy with that of alpha-blocker treatment for lower urinary tract symptoms of benign prostatic hyperplasia. Methods. In a randomized, controlled clinical trial, 52 patients with lower urinary tract symptoms due to benign prostatic hyperplasia received terazosin treatment and 51 underwent microwave treatment under topical anesthesia. The patient evaluation included the International Prostate Symptom Score, peak flow rate, and quality-of-life score before microwave treatment or initiation of terazosin treatment and at periodic intervals thereafter up to 18 months. Results. The mean International Prostate Symptom Score, peak flow rate, and quality-of-life score all improved significantly in both groups by 6 months. However, the magnitude of improvement was significantly greater in the microwave group than in the terazosin group. The significant between-group differences observed at 6 months in the mean International Prostate Symptom Score, peak flow rate, and quality-of-life score were fully maintained at 18 months, at which time the improvements in these three outcome measures were significantly greater (P ), by 35%, 22%, and 43%, respectively, in the microwave group than in the terazosin group. The actuarial rate of treatment failure at 18 months was significantly greater by sevenfold in the terazosin group. Adverse events were generally infrequent and readily manageable in both groups. Conclusions. Although the initial onset of terazosin action was more rapid, the longer term clinical outcomes of targeted microwave treatment were markedly superior. The more favorable results in patients who underwent microwave treatment were maintained for at least 18 months. UROLOGY 57: 66 70, , Elsevier Science Inc. Medical management with alpha-adrenergic receptor blocking agents is the most frequently adopted initial option for patients with lower urinary tract symptoms (LUTS) of benign prostatic hyperplasia (BPH). Alpha-blockade with prazosin analogues such as terazosin or the more recently introduced alpha 1A -adrenoceptor subtype-selective drug tamsulosin is effective in most From the Department of Urology, University of Vienna, Vienna, Austria; and Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas Reprint requests: Bob Djavan, M.D., Ph.D., Department of Urology, University of Vienna, Währinger Gürtel 18-20, A-1090 Vienna, Austria Submitted: June 23, 2000, accepted (with revisions): August 11, 2000 patients with BPH and LUTS and has a rapid onset. On the basis of a recent meta-analysis, these agents are similar in their effectiveness; however, their side-effect profiles differ. 1 The limitations of alphablocking agents are chiefly their side effects and the lack of efficacy in some patients. Transurethral microwave thermotherapy affords a minimally invasive alternative to medical management. The comparative merits of these two approaches to LUTS therapy have been reviewed elsewhere. 2 A single 1-hour outpatient microwave treatment session can result in long-lasting and substantial improvements in symptoms, flow rates, and quality of life (QOL). 3,4 For instance, in a recent study, 74%, 71%, and 79% of patients improved 50% or more in symptoms, peak urinary 2001, ELSEVIER SCIENCE INC /01/$ ALL RIGHTS RESERVED PII S (00)
2 flow rate (Qmax), and QOL score, respectively, by 12 months after microwave treatment. 5 The additional attractions of this therapeutic approach include the low morbidity and the ability to administer microwave treatment under topical anesthesia only. 6 The feasibility of effective microwave treatment in sessions as short as 30 minutes has recently been reported. 7 Also, patients with acute urinary retention due to BPH have been found to be responsive to microwave treatment. 8 A direct comparison of the safety and efficacy between alpha-blockade and microwave treatment has not previously been reported. However, a recent, randomized controlled trial demonstrated markedly superior clinical outcomes at 6 months in patients who underwent microwave therapy compared with those who received alpha-blocking agents. 9 Although the effects of microwave treatment have been shown to be durable for at least as long as 3 years, 10 it remained unclear whether the observed differences in outcome at 6 months between microwave and alpha-blocking therapy might be maintained with longer term follow-up. The present investigation, based on the 18-month follow-up of the patients in the recent randomized trial, was designed to address this question. MATERIAL AND METHODS PATIENTS The participants in this randomized controlled clinical trial at the University of Vienna consisted of 103 patients with moderate to severe LUTS due to BPH. For inclusion in the study, candidates must have been 45 to 85 years old and presented with an International Prostate Symptom Score (IPSS) of 9 or greater; a Qmax less than 12 ml/s with a voided volume of 150 ml or greater; and a prostatic urethral length of 30 to 50 mm as determined by transrectal ultrasound. Patients were excluded on the basis of a history of alpha-blocker usage within the 3 months before study entry, finasteride treatment, prostate surgery or other prostate procedure; a postvoid residual volume greater than 250 ml; neurogenic bladder; acute urinary retention; prostate cancer; prostatitis; bladder cancer; or a prostate volume greater than 100 cm 3. After providing informed written consent, the patients were randomly allocated to terazosin treatment (n 52) or targeted transurethral microwave treatment (n 51). DATA COLLECTION Before treatment, patients furnished their medical history and underwent a physical examination. The pretreatment assessment also included transrectal ultrasound imaging, serum prostate-specific antigen (PSA) assays, and uroflowmetry (Qmax). For IPSS determination, patients completed a selfadministered questionnaire, which included a question to establish the QOL score by the World Health Organization method. Follow-up evaluations of the IPSS, Qmax, and QOL score were conducted during the clinic visits at 2 weeks, 6 weeks, 3 months, 6 months, and 18 months after initiation of terazosin treatment or administration of microwave treatment. TERAZOSIN THERAPY The alpha-blocking regimen comprised 1 mg terazosin (Abbott Laboratories, North Chicago, Ill) daily for 3 days followed by 2 mg daily for 1 week and then 5 mg daily for 2 weeks. In patients attaining less than 35% IPSS improvement compared with baseline, the terazosin dose was increased to 10 mg daily. Terazosin therapy was continued throughout the remainder of the 18-month follow-up period. MICROWAVE TREATMENT Targeted thermoablation of obstructive prostatic tissue was performed using the Targis microwave system (Urologix, Minneapolis, Minn) under topical urethral anesthesia. Microwave power was delivered incrementally to achieve an intraurethral thermosensor temperature of 40 1 C. After the target temperature was reached, microwave power was applied continuously for 1 hour. After treatment, all microwave patients were catheterized for 24 hours, at which time they returned to the clinic for a voiding trial. Patients unable to void after 24 hours remained catheterized and were re-evaluated for the ability to void at 1 and 2 weeks after treatment. STATISTICAL ANALYSIS Data were analyzed using the Scientific Package for Social Sciences, version , statistical software (SPSS, Chicago, Ill). The mean IPSS, Qmax, and QOL score and the corresponding 95% confidence intervals (95% CIs) were calculated. Within-group and between-group differences were evaluated by repeated measures analysis of variance or Student s t test on a two-tailed basis. Differences in the percentages of patients achieving various cumulative improvement percentiles were assessed by the Mann-Whitney U test with last available data carried forward. Actuarial treatment failure rates were evaluated by Kaplan-Meier analysis, and significant between-group differences in failure rate were assessed by log-rank test. RESULTS The baseline patient age, prostate and transition zone volumes, circulating PSA concentration, IPSS, Qmax, and QOL score were similar between the two groups. The changes in the mean IPSS, Qmax, and QOL score throughout the study period are depicted in Figure 1. SYMPTOMS The mean IPSS improved significantly (P ) by 6 months in both treatment groups compared with baseline (Fig. 1). However, the magnitude of the improvement was greater in the microwave group. Thus, the mean IPSS at 6 months in the microwave group (6.8, 95% CI 6.2 to 7.5) was 38% lower (P ) than that in the terazosin group (11.0, 95% CI 10.2 to 11.9). Furthermore, 78% of the microwave group achieved a 50% or greater improvement in IPSS compared with 33% of the terazosin group (P ). The proportion of microwave patients with absolute IPSS improvements of 3 or greater (100%) or 4 or greater (100%) at the last follow-up visit 6 months or less after study entry was significantly larger UROLOGY 57 (1),
3 months of 35% was statistically significant (P ). PEAK FLOW RATE The Qmax increased significantly (P ) compared with the baseline in both groups by 6 months and remained stable thereafter (Fig. 1). The mean Qmax at 6 months in the microwave group (13.9 ml/s, 95% CI 13.2 to 14.6) was 19.8% higher than that in the terazosin group (11.6 ml/s, 95% CI 11.2 to 12.1). The proportion of microwave patients experiencing a 50% or greater Qmax increase at 6 months (65%) markedly exceeded (P ) that of terazosin recipients (10%). At the last follow-up visit 6 months or less after study entry, the proportion of microwave patients with absolute Qmax improvements of 3 ml/s or greater (86%) or 4 ml/s or greater (72%) was significantly higher (P ) than that of the terazosin group (36% and 12%, respectively). At 18 months, the mean Qmax remained similar to the 6-month value in both groups. In the microwave group, the mean Qmax at 18 months (13.8 ml/s, 95% CI 13.2 to 14.5) was 22% higher (P ) than that of terazosin patients (11.3 ml/s, 95% CI 10.9 to 11.7). QOL SCORE The pattern of change in the mean QOL score paralleled that in the mean IPSS (Fig. 1). After declining significantly in both groups by 6 months (P ), the mean QOL score remained near the 6-month level at 18 months. Significant betweengroup differences were, however, apparent at both 6 and 18 months. Thus, the mean microwave group QOL score at 6 months (1.3, 95% CI 1.0 to 1.5) and 18 months (1.3, 95% CI 1.0 to 1.9) was 38% and 43% lower (P ), respectively, than that of the terazosin group at 6 months (2.1, 95% CI 1.9 to 2.4) and 18 months (2.3, 95% CI 2.1 to 2.5). FIGURE 1. Mean (a) IPSS, (b) Qmax, and (c) QOL score in terazosin (closed circles) and microwave (open circles) patients before treatment and during follow-up. Numbers of observations (n) are shown by each data point. Error bars indicate 95% CI. P values are derived from between-group comparisons at the respective time points. (P and P 0.007, respectively) than that of terazosin patients (88% and 86%, respectively). At 18 months, the mean IPSS in both groups remained comparable to the 6-month values. The between-group difference in the mean IPSS at 18 TREATMENT FAILURE Terazosin therapy was considered a failure if the patients discontinued their medication because of either ineffectiveness or side effects. Microwave therapy was considered a failure if the patients required further LUTS therapy such as transurethral resection of the prostate. By 18 months, terazosin therapy had failed in 21 patients, in 13 patients because of ineffectiveness and in 8 because of side effects. Subsequent to terazosin failure, 19 of these patients underwent microwave treatment and 2 underwent transurethral resection of the prostate. Microwave therapy failed in 3 patients by 18 months who then underwent surgery. The actuarial rate of treatment failure at 18 months in the terazosin group (41%, 95% CI 29% to 56%) signif- 68 UROLOGY 57 (1), 2001
4 microwave treatment were urinary tract infection and loss of ejaculate. The cases of urinary tract infection were managed uneventfully by antibiotic medications, with no cases of persistent bacteriuria observed. Catheterization after microwave treatment was required for no longer than 24 hours in 90% of patients, and no microwave patient required catheterization for more than 2 weeks. FIGURE 2. Actuarial treatment failure rate, based on Kaplan-Meier analysis, in the terazosin (solid line) and microwave (dashed line) groups. P value corresponds to between-group difference by log-rank test. Numbers of patients at risk at the indicated time points are displayed above the abscissa. TABLE I. Adverse events Terazosin Group* Microwave Group* Adverse Event 6 mo 18 mo 6 mo 18 mo Dizziness Asthenia Headache Hypotension Nausea Postural dizziness Urinary tract infection Epididymitis Hemospermia Loss of ejaculate Urinary retention 1 wk in duration * Number of adverse events occurring between baseline and 6 months and between 6 and 18 months. icantly exceeded (P ) that in the microwave group (5.9%, 95% CI 2.0% to 17.0%) by approximately sevenfold (Fig. 2). ADVERSE EVENTS Most adverse events were encountered during the first 6 months, with fewer occurring in the interval from 6 to 18 months (Table I). The adverse events in the terazosin group from baseline to 6 months and from 6 months to 18 months totaled 17 and 6, respectively, compared with 7 and 5, respectively, for the microwave group. The most commonly occurring adverse events of terazosin were dizziness, asthenia, and headache; those for COMMENT The present data reveal that the superior clinical outcomes after microwave treatment compared with alpha-blockade previously demonstrated at 6 months 9 are fully maintained at 18 months. Significantly more favorable results at 18 months were observed in IPSS, Qmax, and QOL, and no evidence of a diminution in the between-group differences observed at 18 months compared with at 6 months was found. The magnitude of symptomatic improvement in the terazosin group was similar to that reported in prior investigations of alphablockade, and consequently the difference in improvement compared with microwave patients is unlikely to be due in any substantial part to inadequate terazosin dose titration. Adverse events in both groups were infrequent and readily manageable. The types of adverse events experienced by the two groups were distinct and nonoverlapping. The additional adverse events occurring in the 6 to 18-month interval were of comparable frequency in the terazosin and microwave groups. The limitations of the present study included the investigation of only a single alpha-blocking agent and the lack of a placebo or sham arm and placebo lead-in period. Nonetheless, in previous studies, marked differences have not been apparent in the magnitude of placebo effects in terazosin recipients 11,12 compared with that of sham effects in microwave patients. 3,4 Furthermore, improvements in the mean IPSS and Qmax with terazosin and microwave treatment have generally exceeded those of a placebo and sham procedure, respectively, by twofold to sevenfold. The treatment failure rate was significantly lower in the microwave group. This difference should, however, be interpreted with caution, since qualitatively different criteria were applied for scoring failure. Unlike terazosin recipients, microwave patients did not, for example, have the alternative of discontinuing treatment. Nevertheless, the sevenfold magnitude in the difference at 18 months was striking. Most early failures in the terazosin group were due to side effects; later failures were predominantly ascribable to a lack of efficacy. One advantage of terazosin, as previously described, 9 is its more rapid onset of action. Maximal UROLOGY 57 (1),
5 effects were manifested within 6 weeks compared with 6 months for microwave treatment. The earlier onset of action with alpha-blockade and the greater long-term efficacy of microwave treatment suggest the potential advantages of combining the two modalities, either sequentially or concurrently. This possibility has recently been investigated in a randomized controlled trial of 41 patients with BPH who underwent microwave treatment with or without neoadjuvant and adjuvant tamsulosin administration. The combination regimen resulted in significantly lower mean IPSSs at 2 weeks and 6 weeks than those of the microwave-only group. 13 Thus, neoadjuvant and adjuvant alpha-blockade combined with microwave treatment might promote early relief and more substantial long-term improvement. However, recent evidence suggests even greater early improvement after microwave treatment in patients receiving an intraurethral prostatic bridge-catheter compared with neoadjuvant and adjuvant tamsulosin administration. 14 CONCLUSIONS Terazosin treatment rapidly improves symptoms, voiding function, and QOL in patients with BPH and LUTS and may be preferred by some patients over a procedural intervention. Nevertheless, markedly superior outcomes are demonstrable by 6 months in patients receiving microwave treatment, and this superiority is fully maintained for at least as long as 18 months. This modality may be preferred by patients desiring a single definitive treatment conferring durable, substantial benefit. REFERENCES 1. Djavan B, and Marberger M: A meta-analysis on the efficacy and tolerability of 1 -adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 36: 1 13, Djavan B, Larson TR, Blute ML, et al: Transurethral microwave thermotherapy: what role should it play versus medical management in the treatment of benign prostatic hyperplasia? Urology 52: , Larson TR, Blute ML, Bruskewitz RC, et al: A highefficiency microwave thermoablation system for the treatment of benign prostatic hyperplasia: results of a randomized, sham-controlled, prospective, double-blind, multicenter clinical trial. Urology 51: , Roehrborn CG, Preminger G, Newhall P, et al: Microwave thermotherapy for benign prostatic hyperplasia with the Dornier Urowave: results of a randomized, double-blind, multicenter, sham-controlled trial. Urology 51: 19 28, Djavan B, Bursa B, Basharkhah A, et al: Pretreatment prostate-specific antigen as an outcome predictor of targeted transurethral microwave thermotherapy. Urology 55: 51 57, Djavan B, Shariat S, Schäfer B, et al: Tolerability of high energy transurethral microwave thermotherapy with topical urethral anesthesia: results of a prospective, randomized, single-blinded clinical trial. J Urol 160: , Hammond GW: Targis microwave therapy, 60 minutes vs. 30 minute treatment: 1 year results. J Urol 163(suppl): 271, Djavan B, Seitz C, Ghawidel K, et al: High-energy transurethral microwave thermotherapy in patients with acute urinary retention due to benign prostatic hyperplasia. Urology 54: 18 22, Djavan B, Roehrborn CG, Shariat S, et al: Prospective randomized comparison of high energy transurethral microwave thermotherapy versus -blocker treatment of patients with benign prostatic hyperplasia. J Urol 161: , Ramsey EW, Miller PD, and Parsons K: Transurethral microwave thermotherapy in the treatment of benign prostatic hyperplasia: results obtained with the Urologix T3 device. World J Urol 16: , Lepor H, Williford WO, Barry MJ, et al: The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med 335: , Roehrborn CG, Oesterling JE, Auerbach S, et al, and the HYCAT Investigator Group: The Hytrin Community Assessment Trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. Urology 47: , Djavan B, Shariat S, Fakhari M, et al: Neoadjuvant and adjuvant -blockade improves early results of high-energy transurethral microwave thermotherapy for lower urinary tract symptoms of benign prostatic hyperplasia: a randomized, prospective clinical trial. Urology 53: , Djavan B, Fakhari M, Shariat S, et al: A novel intraurethral prostatic bridge catheter for prevention of temporary prostatic obstruction following high energy transurethral microwave thermotherapy in patients with benign prostatic hyperplasia. J Urol 161: , UROLOGY 57 (1), 2001
The MTOPS Study: New Findings, New Insights, and Clinical Implications for the Management of BPH
european urology supplements 5 (2006) 628 633 available at www.sciencedirect.com journal homepage: www.europeanurology.com The MTOPS Study: New Findings, New Insights, and Clinical Implications for the
More informationUniversity at Buffalo School of Pharmacy and Pharmaceutical Sciences Drug Information Response Documentation
University at Buffalo School of Pharmacy and Pharmaceutical Sciences Drug Information Response Documentation Module Dates: 10/24/05-11/30/05 Name of Clerkship: Applied Pharmacotherapy Preceptor Name: Dr.
More information150640_Brochure_B 4/12/07 2:58 PM Page 2. Patient Information. Freedom From an Enlarged Prostate
150640_Brochure_B 4/12/07 2:58 PM Page 2 Patient Information Freedom From an Enlarged Prostate 150640_Brochure_B 4/12/07 2:58 PM Page 3 GreenLight Laser Therapy 1 150640_Brochure_B 4/12/07 2:58 PM Page
More informationThe correlation of symptoms severity and objective measures in patients with lower urinary tract symptoms
Clinical Medicine Research 2013; 2(6): 135-139 Published online October 20, 2013 (http://www.sciencepublishinggroup.com/j/cmr) doi: 10.11648/j.cmr.20130206.14 The correlation of symptoms severity and objective
More informationStudy Design Of Medical Research
Study Design Of Medical Research By Ahmed A.Shokeir, MD,PHD, FEBU Prof. Urology, Urology & Nephrology Center, Mansoura, Egypt Study Designs In Medical Research Topics Classification Case series studies
More informationOveractive Bladder and/or Nocturia (Female)
Overactive Bladder and/or Nocturia (Female) Definition: Increased urinary frequency > 8 voids / day More than 1 void/night in women 80 years old Diagnosis
More informationAlpha-Blocker Patient Advisory ASCRS and AAO Information Statement
Alpha-Blocker Patient Advisory ASCRS and AAO Information Statement Alpha-blocker drugs and intraoperative floppy iris syndrome (IFIS), related complications in cataract surgery Recommendations The American
More informationAmerican Urological Association Guideline: Management of Benign Prostatic Hyperplasia (BPH)
American Urological Association Guideline: Management of Benign Prostatic Hyperplasia (BPH) Revised, 2010 Panel Members: Kevin T. McVary, MD (Chair) Claus G. Roehrborn, MD (Co-Chair) Andrew L. Avins, MD,
More informationBothersome urinary symptoms and disease-specific quality of life in patients with benign prostatic obstruction
Scandinavian Journal of Urology and Nephrology, 2007; 41: 3241 ORIGINAL ARTICLE Bothersome urinary symptoms and disease-specific quality of life in patients with benign prostatic obstruction High prevalence
More informationSummary 1. Comparative-effectiveness
Cost-effectiveness of Delta-9-tetrahydrocannabinol/cannabidiol (Sativex ) as add-on treatment, for symptom improvement in patients with moderate to severe spasticity due to MS who have not responded adequately
More informationMedical Treatment of Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia
european urology supplements 8 (2009) 496 503 available at www.sciencedirect.com journal homepage: www.europeanurology.com Medical Treatment of Lower Urinary Tract Symptoms Suggestive of Benign Prostatic
More informationStudy Design. Date: March 11, 2003 Reviewer: Jawahar Tiwari, Ph.D. Ellis Unger, M.D. Ghanshyam Gupta, Ph.D. Chief, Therapeutics Evaluation Branch
BLA: STN 103471 Betaseron (Interferon β-1b) for the treatment of secondary progressive multiple sclerosis. Submission dated June 29, 1998. Chiron Corp. Date: March 11, 2003 Reviewer: Jawahar Tiwari, Ph.D.
More informationRiociguat Clinical Trial Program
Riociguat Clinical Trial Program Riociguat (BAY 63-2521) is an oral agent being investigated as a new approach to treat chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension
More informationPrimary Care Management of Male Lower Urinary Tract Symptoms. Matthew B.K. Shaw Consultant Urological Surgeon
Primary Care Management of Male Lower Urinary Tract Symptoms Matthew B.K. Shaw Consultant Urological Surgeon NICE LUTS Guidelines Lower Urinary Tract Symptoms (LUTS) in men. NICE Clinical Guideline 97
More informationChapter 31: Lower Urinary Tract Conditions in Elderly Patients
Chapter 31: Lower Urinary Tract Conditions in Elderly Patients Damon Dyche and Jay Hollander William Beaumont Hospital, Royal Oak, Michigan As our population ages, the number of patients presenting to
More informationClinical Trial Design. Sponsored by Center for Cancer Research National Cancer Institute
Clinical Trial Design Sponsored by Center for Cancer Research National Cancer Institute Overview Clinical research is research conducted on human beings (or on material of human origin such as tissues,
More information7. Prostate cancer in PSA relapse
7. Prostate cancer in PSA relapse A patient with prostate cancer in PSA relapse is one who, having received a primary treatment with intent to cure, has a raised PSA (prostate-specific antigen) level defined
More informationMANAGEMENT OF PROSTATE ENLARGEMENT/BPH
MANAGEMENT OF PROSTATE ENLARGEMENT/BPH J E S S I C A E. P A O N E S S A, M. D. A S S I S T A N T P R O F E S S O R D E P A R T M E N T O F U R O L O G Y S U N Y U P S T A T E M E D I C A L U N I V E R
More informationVictoria Sharp, MD, MBA, FAAFP
Victoria Sharp, MD, MBA, FAAFP Clinical Professor of Urology and Family Medicine Victoria Sharp, MD, MBA, FAAFP Market Chief Medial Officer AmeriHealth Caritas Family of Companies Office phone: (515) 330-3740
More informationsurg urin Surgery: Urinary System 1
Surgery: Urinary System 1 This section contains information to assist providers in billing for surgical procedures related to the urinary system. Extracorporeal Shock Wave Lithotripsy Medi-Cal covers Extracorporeal
More informationDrugs for MS.Drug fact box cannabis extract (Sativex) Version 1.0 Author
Version History Policy Title Drugs for MS.Drug fact box cannabis extract (Sativex) Version 1.0 Author West Midlands Commissioning Support Unit Publication Date Jan 2013 Review Date Supersedes/New (Further
More informationFAQ About Prostate Cancer Treatment and SpaceOAR System
FAQ About Prostate Cancer Treatment and SpaceOAR System P. 4 Prostate Cancer Background SpaceOAR Frequently Asked Questions (FAQ) 1. What is prostate cancer? The vast majority of prostate cancers develop
More information1. What is the prostate-specific antigen (PSA) test?
1. What is the prostate-specific antigen (PSA) test? Prostate-specific antigen (PSA) is a protein produced by the cells of the prostate gland. The PSA test measures the level of PSA in the blood. The doctor
More informationHistorical Basis for Concern
Androgens After : Are We Ready? Mohit Khera, MD, MBA Assistant Professor of Urology Division of Male Reproductive Medicine and Surgery Scott Department of Urology Baylor College of Medicine Historical
More informationASCO/AUA Special Announcement on FDA Decision Re: Dutasteride
ASCO/AUA Special Announcement on FDA Decision Re: Dutasteride Special Announcement (Update 12/11/12): The American Society of Clinical Oncology (ASCO) and the American Urological Association (AUA) have
More informationRita Willener, Clinical Nurse Specialist Department of Urology, University Hospital Berne Switzerland rita.willener@insel.ch phone: 0041 31 632 47 45
Authors: Willener R., CNS,, Spichiger E., RN, PhD, Head office of Nursing University Hospital Berne, Hantikainen V., RN, PhD, Head office of Nursing University Hospital Berne, Patients experience of postoperative
More informationHigh Power Diode Laser Vaporization of the Prostate: Preliminary Results for Benign Prostatic Hyperplasia
High Power Diode Laser Vaporization of the Prostate: Preliminary Results for Benign Prostatic Hyperplasia Ali Erol, Kamil Cam,* Ali Tekin, Omur Memik, Soner Coban and Yavuz Ozer From the Department of
More informationKanıt: Klinik çalışmalarda ZYTIGA
mkdpk de Sonunda Gerçek İlerleme! Kanıt: Klinik çalışmalarda ZYTIGA Dr. Sevil Bavbek 5. Türk Tıbbi Onkoloji Kongresi Mart 214, Antalya Endocrine therapies Adrenals Testis Abiraterone Orteronel Androgen
More informationDurability of the Prostatic Urethral Lift: 2-Year Results of the L.I.F.T. Study
urologypracticejournal.com Durability of the Prostatic Urethral Lift: 2-Year Results of the L.I.F.T. Study Claus G. Roehrborn,*,y Steven N. Gange, y Neal D. Shore, z Jonathan L. Giddens, z Damien M. Bolton,
More informationPSA Testing 101. Stanley H. Weiss, MD. Professor, UMDNJ-New Jersey Medical School. Director & PI, Essex County Cancer Coalition. weiss@umdnj.
PSA Testing 101 Stanley H. Weiss, MD Professor, UMDNJ-New Jersey Medical School Director & PI, Essex County Cancer Coalition weiss@umdnj.edu September 23, 2010 Screening: 3 tests for PCa A good screening
More informationGuidelines for the Use of Controlled Substances in the Treatment of Pain Adopted by the New Hampshire Medical Society, July 1998
Guidelines for the Use of Controlled Substances in the Treatment of Pain Adopted by the New Hampshire Medical Society, July 1998 Section I: Preamble The New Hampshire Medical Society believes that principles
More informationPSA Screening for Prostate Cancer Information for Care Providers
All men should know they are having a PSA test and be informed of the implications prior to testing. This booklet was created to help primary care providers offer men information about the risks and benefits
More informationVersion History. Previous Versions. Drugs for MS.Drug facts box fampridine Version 1.0 Author
Version History Policy Title Drugs for MS.Drug facts box fampridine Version 1.0 Author West Midlands Commissioning Support Unit Publication Date Jan 2013 Review Date Supersedes/New (Further fields as required
More information2.0 Synopsis. Vicodin CR (ABT-712) M05-765 Clinical Study Report R&D/07/095. (For National Authority Use Only) to Part of Dossier: Volume:
2.0 Synopsis Abbott Laboratories Name of Study Drug: Vicodin CR Name of Active Ingredient: Hydrocodone/Acetaminophen Extended Release (ABT-712) Individual Study Table Referring to Part of Dossier: Volume:
More informationTreatment of Incidental Prostate Cancer Diagnosed during BPH Surgery with Radical Prostatectomy: Appropriate or over Treatment?
Journal of Cancer Therapy, 2012, 3, 256-262 http://dx.doi.org/10.4236/jct.2012.34036 Published Online August 2012 (http://www.scirp.org/journal/jct) Treatment of Incidental Prostate Cancer Diagnosed during
More informationCARE PROCESS STEP EXPECTATIONS RATIONALE
URINARY INCONTINENCE CARE PROCESS STEP EXPECTATIONS RATIONALE ASSESSMENT/PROBLEM RECOGNITION 1. Did the staff and physician seek and document risk factors for urinary incontinence and any history of urinary
More informationCase Based Urology Learning Program
Case Based Urology Learning Program Resident s Corner: UROLOGY Case Number 21 CBULP 2011 068 Case Based Urology Learning Program Editor: Associate Editors: Manager: Case Contributors: Steven C. Campbell,
More informationRole of MRI in the Diagnosis of Prostate Cancer, A Proposal
Clinical and Experimental Medical Sciences, Vol. 1, 2013, no. 3, 111 116 HIKARI Ltd, www.m-hikari.com Role of MRI in the Diagnosis of Prostate Cancer, A Proposal W. Akhter Research Fellow Urology, Bartshealth
More informationSponsor Novartis. Generic Drug Name Secukinumab. Therapeutic Area of Trial Psoriasis. Approved Indication investigational
Clinical Trial Results Database Page 2 Sponsor Novartis Generic Drug Name Secukinumab Therapeutic Area of Trial Psoriasis Approved Indication investigational Clinical Trial Results Database Page 3 Study
More informationBehavioral and Physical Treatments for Tension-type and Cervicogenic Headache
Evidence Report: Behavioral and Physical Treatments for Tension-type and Cervicogenic Headache Douglas C. McCrory, MD, MHSc Donald B. Penzien, PhD Vic Hasselblad, PhD Rebecca N. Gray, DPhil Duke University
More informationTo decrease and/or prevent the incidence of catheter associated infections and other complications associated with IUC.
Patient Care Manual Standardized Procedure Number: PC-SP.115 Latest Revision Date: 01/27/2015 Effective Date: 10/10/2011 Standardized Procedure: Urethral Catheter (IUC), Adult, Discontinuance of FUNCTION
More informationIssues Regarding Use of Placebo in MS Drug Trials. Peter Scott Chin, MD Novartis Pharmaceuticals Corporation
Issues Regarding Use of Placebo in MS Drug Trials Peter Scott Chin, MD Novartis Pharmaceuticals Corporation Context of the Guidance The draft EMA Guidance mentions placebo as a comparator for superiority
More informationKELLI DEWITT WHITEHEAD, RN, MS, ARNP
CIRRICULUM VITAE KELLI DEWITT WHITEHEAD, RN, MS, ARNP Associated Urologist, PA 341 Wheatfield, Suite 180 Sunnyvale, TX 75182 972-270-8859 EDUCATION Master of Science, Family Nurse Practitioner University
More informationClinical Spotlight in Breast Cancer
2015 European Oncology Congress in Vienna Clinical Spotlight in Breast Cancer Reference Slide Deck Abstract #1815 Impact of Palbociclib Plus Fulvestrant on Global QOL, Functioning, and Symptoms Compared
More informationTestosterone; What s all the hype? KRISTEN WYRICK, LTCOL,USAFR, MC USUHS, FAMILY MEDICINE JOINT BASE LANGLEY-EUSTIS
Testosterone; What s all the hype? KRISTEN WYRICK, LTCOL,USAFR, MC USUHS, FAMILY MEDICINE JOINT BASE LANGLEY-EUSTIS The faces of Low Testosterone What your patients are seeing Pharmacy Industry Testosterone
More informationOVERACTIVE BLADDER DIAGNOSIS AND TREATMENT OF OVERACTIVE BLADDER IN ADULTS:
2014 OVERACTIVE BLADDER DIAGNOSIS AND TREATMENT OF OVERACTIVE BLADDER IN ADULTS: AUA/SUFU Guideline (2012); Amended (2014) For Primary Care Providers OVERACTIVE BLADDER Diagnosis and Treatment of Overactive
More informationHumulin (LY041001) Page 1 of 1
(LY041001) These clinical study results are supplied for informational purposes only in the interests of scientific disclosure. They are not intended to substitute for the FDA-approved package insert or
More informationEmergency Room Treatment of Psychosis
OVERVIEW The term Lewy body dementias (LBD) represents two clinical entities dementia with Lewy bodies (DLB) and Parkinson s disease dementia (PDD). While the temporal sequence of symptoms is different
More informationSYNOPSIS. 2-Year (0.5 DB + 1.5 OL) Addendum to Clinical Study Report
Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Abatacept () Name of Active Ingredient: Abatacept () Individual Study Table Referring to the Dossier (For National Authority Use
More informationU.S. Scientific Update Aricept 23 mg Tablets. Dr. Lynn Kramer President NeuroScience Product Creation Unit Eisai Inc.
U.S. Scientific Update Aricept 23 mg Tablets Dr. Lynn Kramer President NeuroScience Product Creation Unit Eisai Inc. Unmet Need in Moderate to Severe Alzheimer s Disease (AD) Ongoing clinical deterioration
More informationMeasure #257 (NQF 1519): Statin Therapy at Discharge after Lower Extremity Bypass (LEB) National Quality Strategy Domain: Effective Clinical Care
Measure #257 (NQF 1519): Statin Therapy at Discharge after Lower Extremity Bypass (LEB) National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY
More informationon behalf of the AUGMENT-HF Investigators
One Year Follow-Up Results from AUGMENT-HF: A Multicenter Randomized Controlled Clinical Trial of the Efficacy of Left Ventricular Augmentation with Algisyl-LVR in the Treatment of Heart Failure* Douglas
More informationTestosterone safety and the prostate
Testosterone safety and the prostate Professor Dr. Ridwan Shabsigh Director, Division of Urology, Maimonides Medical Center, Brooklyn, NY, Professor of Clinical Urology, College of Physicians and Surgeons,
More informationForm B-1. Inclusion form for the effectiveness of different methods of toilet training for bowel and bladder control
Form B-1. Inclusion form for the effectiveness of different methods of toilet training for bowel and bladder control Form B-2. Assessment of methodology for non-randomized controlled trials for the effectiveness
More informationIntroduction. Lower urinary tract symptoms (LUTS), in men over 50 years of age most commonly attributable to benign
Prospective multi-center study elucidating patient experience after prostatic urethral lift Neal Shore, MD, 1 Sheldon Freedman, MD, 2 Steven Gange, MD, 3 William Moseley, MD, 4 Sean Heron, MD, 5 Ron Tutrone,
More informationMichigan Guidelines for the Use of Controlled Substances for the Treatment of Pain
Michigan Guidelines for the Use of Controlled Substances for the Treatment of Pain Section I: Preamble The Michigan Boards of Medicine and Osteopathic Medicine & Surgery recognize that principles of quality
More information151557_GreenLightSummary_B 5/31/07 4:29 PM Page 1
151557_GreenLightSummary_B 5/31/7 4:29 PM Page 1 151557_GreenLightSummary_B 5/31/7 4:29 PM Page 2 Definitions: TURP (Transurethral Resection of the Prostate) Generally regarded as the gold standard surgical
More informationRATE VERSUS RHYTHM CONTROL OF ATRIAL FIBRILLATION: SPECIAL CONSIDERATION IN ELDERLY. Charles Jazra
RATE VERSUS RHYTHM CONTROL OF ATRIAL FIBRILLATION: SPECIAL CONSIDERATION IN ELDERLY Charles Jazra NO CONFLICT OF INTEREST TO DECLARE Relationship Between Atrial Fibrillation and Age Prevalence, percent
More informationNICE Pathways bring together all NICE guidance, quality standards and other NICE information on a specific topic.
Initial assessment and investigation of urinary incontinence bring together all NICE guidance, quality standards and other NICE information on a specific topic. are interactive and designed to be used
More informationLEMUTEPORFIN INJECTABLE FOR BENIGN PROSTATIC HYPERPLASIA MARKETING PLAN FOR QLT INC.
LEMUTEPORFIN INJECTABLE FOR BENIGN PROSTATIC HYPERPLASIA MARKETING PLAN FOR QLT INC. NataSa Jovic Quinn Graduate Diploma, Business Administration, Simon Fraser University, 2004 PROJECT SUBMITTED IN PARTIAL
More informationPSA screening in asymptomatic men the debate continues www.bpac.org.nz keyword: psa
PSA screening in asymptomatic men the debate continues www.bpac.org.nz keyword: psa Key messages: PSA is present in the benign and malignant prostate There is currently no national screening programme
More informationCOMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP)
The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use London, 18 December 2002 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON THE
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of the clinical
More informationAdult Urodynamics: American Urological Association (AUA)/Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) Guideline
Adult Urodynamics: American Urological Association (AUA)/Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) Guideline RECOMMENDATIONS 1 Conditional: Clinicians who are making
More informationLOW LEVELS OF PROSTATE-SPECIFIC ANTIGEN PREDICT LONG-TERM RISK OF PROSTATE CANCER: RESULTS FROM THE BALTIMORE LONGITUDINAL STUDY OF AGING
ADULT UROLOGY CME ARTICLE LOW LEVELS OF PROSTATE-SPECIFIC ANTIGEN PREDICT LONG-TERM RISK OF PROSTATE CANCER: RESULTS FROM THE BALTIMORE LONGITUDINAL STUDY OF AGING JUNYONG FANG, E. JEFFREY METTER, PATRICIA
More informationAcute urinary retention evaluated with urodynamic assessment in elder male W23, 16 October 2012 09:00-10:30
Acute urinary retention evaluated with urodynamic assessment in elder male W23, 16 October 2012 09:00-10:30 Start End Topic Speakers 09:00 09:05 Introduction Jianquan Hou 09:05 09:20 Acute urinary retention
More informationPSA Testing for Prostate Cancer An information sheet for men considering a PSA Test
PSA Testing for Prostate Cancer An information sheet for men considering a PSA Test What is the aim of this leaflet? Prostate cancer is a serious condition. The PSA test, which can give an early indication
More informationDiagnosis of Prostate Cancer: Repeated Transrectal Prostate Biopsy or Transurethral Resection
ORIGINAL ARTICLE Diagnosis of Prostate Cancer: Repeated Transrectal Prostate Biopsy or Transurethral Resection Chih-Chieh Lin 1, William J.S. Huang 1,3 *, Li-Ju Wu 2, Yen-Hwa Chang 1,3, Alex T.L. Lin 1,3,
More informationPROSTATE ENLARGEMENT A GUIDE TO URINARY SYMPTOMS IN MEN A BOOKLET IN THE SERIES OF CONSUMER GUIDES ON MALE REPRODUCTIVE HEALTH FROM
PROSTATE ENLARGEMENT A GUIDE TO URINARY SYMPTOMS IN MEN A BOOKLET IN THE SERIES OF CONSUMER GUIDES ON MALE REPRODUCTIVE HEALTH FROM AT A GLANCE First published in March 2004 by Andrology Australia 4th
More informationTreatment and Surveillance of Non- Muscle Invasive Bladder Cancer
Treatment and Surveillance of Non- Muscle Invasive Bladder Cancer David Josephson, MD FACS Fellowship Director, Urologic Oncology and Robotic Surgery Program Staging Most important in risk assessment and
More informationOfficial reprint from UpToDate www.uptodate.com 2013 UpToDate
Official reprint from UpToDate www.uptodate.com 2013 UpToDate The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek
More informationVersion History. Previous Versions. Drugs for MS.Drug facts box fingolimod Version 1.0 Author
Version History Policy Title Drugs for MS.Drug facts box fingolimod Version 1.0 Author West Midlands Commissioning Support Unit Publication Date Jan 2013 Review Date Supersedes/New (Further fields as required
More informationCase Study Activity: Managing Overactive Bladder in the Community Pharmacy Answers to Interactive Questions and Resources
Case Study Activity: Managing Overactive Bladder in the Community Pharmacy Answers to Interactive Questions and Resources Case 3: Updates on Overactive Bladder Treatments Activity Preview Overactive bladder
More informationPreservation and Incorporation of Valuable Endoscopic Innovations (PIVI)
Preservation and Incorporation of Valuable Endoscopic Innovations (PIVI) The American Society for Gastrointestinal Endoscopy PIVI on Endoscopic Bariatric Procedures (short form) Please see related White
More informationAn Introduction to PROSTATE CANCER
An Introduction to PROSTATE CANCER Being diagnosed with prostate cancer can be a life-altering experience. It requires making some very difficult decisions about treatments that can affect not only the
More informationAntibiotic Prophylaxis for Short-term Catheter Bladder Drainage in adults. A Systematic Review (Cochrane database August 2013)
Antibiotic Prophylaxis for Short-term Catheter Bladder Drainage in adults A Systematic Review (Cochrane database August 2013) Gail Lusardi, Senior Lecturer Dr Allyson Lipp, Principal Lecturer, Dr Chris
More informationProstate Specific Antigen (PSA) Blood Test
TO PROVIDE THE VERY BEST CARE FOR EACH PATIENT ON EVERY OCCASION Prostate Specific Antigen (PSA) Blood Test An information guide Prostate Specific Antigen (PSA) Blood Test Prostate Specific Antigen (PSA)
More informationNew Evidence reports on presentations given at EULAR 2012. Rituximab for the Treatment of Rheumatoid Arthritis
New Evidence reports on presentations given at EULAR 2012 Rituximab for the Treatment of Rheumatoid Arthritis Report on EULAR 2012 presentations Long-term safety of rituximab: 10-year follow-up in the
More informationOral Zinc Supplementation as an Adjunct Therapy in the Management of Hepatic Encephalopathy: A Randomized Controlled Trial
Oral Zinc Supplementation as an Adjunct Therapy in the Management of Hepatic Encephalopathy: A Randomized Controlled Trial Marcus R. Pereira A. Study Purpose Hepatic encephalopathy is a common complication
More informationThe prevalence of benign prostatic
Common Questions About the Diagnosis and Management of Benign Prostatic Hyperplasia RYAN PEARSON, MD, Kaiser Permanente, Folsom, California PAMELA M. WILLIAMS, MD, Mike O Callaghan Federal Medical Center,
More informationComparative Effectiveness Review Number 140. Chronic Urinary Retention: Comparative Effectiveness and Harms of Treatments
Comparative Effectiveness Review Number 140 Chronic Urinary Retention: Comparative Effectiveness and Harms of Treatments Comparative Effectiveness Review Number 140 Chronic Urinary Retention: Comparative
More informationUpdate on Buprenorphine: Induction and Ongoing Care
Update on Buprenorphine: Induction and Ongoing Care Elizabeth F. Howell, M.D., DFAPA, FASAM Department of Psychiatry, University of Utah School of Medicine North Carolina Addiction Medicine Conference
More informationBenign Prostatic Hyperplasia: A Case-Based Approach
Benign Prostatic Hyperplasia: A Case-Based Approach Benign Prostatic Hyperplasia: A Case-Based Approach Release Date: December 15, 2003 Expiration Date: December 14, 2006 Target Audience: Physicians, pharmacists,
More informationBefore, Frank's immune cells could
Before, Frank's immune cells could barely recognize a prostate cancer cell. Now, they are focused on it. Stimulate an immune response against advanced prostate cancer Extend median survival beyond 2 years
More informationProstate cancer is the most common cause of death from cancer in men over age 75. Prostate cancer is rarely found in men younger than 40.
A.D.A.M. Medical Encyclopedia. Prostate cancer Cancer - prostate; Biopsy - prostate; Prostate biopsy; Gleason score Last reviewed: October 2, 2013. Prostate cancer is cancer that starts in the prostate
More informationShared Care Guideline-Use of Donepezil, Galantamine, Rivastigmine and Memantine in Dementia
Shared Care Guideline-Use of Donepezil, Galantamine, Rivastigmine and Memantine in Dementia Version: 3.0 Ratified by: Medicines Committee Date ratified: 16 th November 2011 Name of originator/author: James
More informationIf several different trials are mentioned in one publication, the data of each should be extracted in a separate data extraction form.
General Remarks This template of a data extraction form is intended to help you to start developing your own data extraction form, it certainly has to be adapted to your specific question. Delete unnecessary
More informationCHOICE OF CONTROL GROUP AND RELATED ISSUES IN CLINICAL TRIALS E10
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE CHOICE OF CONTROL GROUP AND RELATED ISSUES IN CLINICAL
More informationNovel Anticoagulation Agents DISCLOSURES. Objectives ATRIAL FIBRILLATION TRIALS. NOAC Comparison 6/12/2015
Novel Anticoagulation Agents DISCLOSURES James W. Haynes, MD Department of Family Medicine Univ of TN Health Science Center (Chattanooga) Objectives Understand mechanism of action behind the NOAC agents
More informationA 5-HT 6 antagonist in advanced development for the treatment of mild and moderate Alzheimer s disease: idalopirdine (Lu AE58054)
A 5-HT 6 antagonist in advanced development for the treatment of mild and moderate Alzheimer s disease: idalopirdine (Lu AE58054) producti Congrès National des unités de soins, d'évaluation et de prise
More informationTESTOSTERONE The Future?
TESTOSTERONE The Future? Martin M. Miner MD Co-Director Men s Health Center The Miriam Hospital Clinical Professor of Family Medicine and Urology Warren Alpert School of Medicine of Brown University Providence,
More informationCase Series on Chronic Whiplash Related Neck Pain Treated with Intraarticular Zygapophysial Joint Regeneration Injection Therapy
Pain Physician 2007; 10:313-318 ISSN 1533-3159 Case Series Case Series on Chronic Whiplash Related Neck Pain Treated with Intraarticular Zygapophysial Joint Regeneration Injection Therapy R. Allen Hooper
More informationPSA: Prostate Cancer Screening
PSA: Prostate Cancer Screening 42 nd Annual Convention of the Philippines College of Physicians May 7, 2012, SMX Convention Center Jose Albert Cruz Reyes III, MD, FPCS, FPUA, DPBU Institute of Urology
More informationPREVENTION OF CATHETER ASSOCIATED URINARY TRACT INFECTIONS. (CAUTIs)
PREVENTION OF CATHETER ASSOCIATED URINARY TRACT INFECTIONS (CAUTIs) CAUTIs A UTI where an indwelling urinary catheter was in place for >2 calendar days on the date of event. OR If an indwelling urinary
More informationREPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group
REPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group In the 2002 edition of the ASCO meeting, a total of 315 abstracts in the field of respiratory
More informationClinical evaluation of Himplasia in Benign Prostatic Hyperplasia: An Open Clinical Trial
[Medicine Update (2003): (11), 1, 75-78] Clinical evaluation of Himplasia in Benign Prostatic Hyperplasia: An Open Clinical Trial Manoranjan Sahu, Reader and Head, Ramesh Bhat, P. Research Scholar, Department
More informationBEST in MH clinical question-answering service
Best Evidence Summaries of Topics in Mental Healthcare BEST in MH clinical question-answering service Question In people with PTSD (including single and multiple event trauma) how effective is prazosin
More informationUse Of Testosterone In Men With Prostate Cancer. Traditional view: T is dangerous for PCa
Use Of Testosterone In Men With Prostate Cancer Abraham Morgentaler, MD, FACS Director, Men s s Health Boston Associate Clinical Professor of Urology Harvard Medical School Boston, USA Traditional view:
More informationMedical Tests for Prostate Problems
Medical Tests for Prostate Problems National Kidney and Urologic Diseases Information Clearinghouse U.S. Department of Health and Human Services NATIONAL INSTITUTES OF HEALTH What is the prostate? The
More information